Key Takeaways
- Health Secretary RFK Jr. proposes FDA enforcement discretion on unproven peptides.
- FDA plans to ease access despite safety concerns raised by scientists.
- Proposal aims to provide assurance to specialty pharmacies.
Health Secretary Robert F. Kennedy Jr. is reportedly pushing for the Food and Drug Administration (FDA) to ease restrictions on unproven peptide drugs, according to a report by The Associated Press.
The FDA has submitted an 'Interim Access Policy' on peptides for review by the White House, a filing notice on an Office of Management and Budget website indicates.
People familiar with the proposal told The Associated Press that it would grant the FDA 'enforcement discretion' on certain peptide drugs, allowing the agency to choose not to enforce current restrictions.
This move is aimed at providing assurance to specialty pharmacies eager to start making these drugs, ensuring they will not face targeted enforcement by the FDA.
The proposal comes despite concerns raised by FDA staff scientists who found that the drugs have not been sufficiently studied to establish safety and efficacy, potentially causing harm.
The Department of Health and Human Services, which oversees the FDA, did not respond to a request for comment from Ars Technica.
The move has raised eyebrows among public health advocates who fear it could compromise patient safety.
Specialty pharmacies, however, see this as a potential breakthrough, as they have been eager to offer these unproven peptide drugs to patients.
The proposal is currently under review by the White House, and its final outcome remains uncertain.
